[1] Ahamad A, Jhingran A. New radiation techniques in gynecological cancer[J]. Int Gynecol Cancer, 2004, 14(3):569-579.
[2] Vogel WV, Oyen WJ, BarentszJO, et al. PET-CT:panacea,redundary, or something in between?[J]. J Nucl Med, 2004, 45(1S):15-24.
[3] Bradley JD, Perez CA, Dehdashti F, et al. Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer[J]. J Nucl Med, 2004, 45(1S):96-101.
[4] Brahme A. Recent advances in light ion radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2004, 58(2):603-616.
[5] Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomographcomputerized tomography imaging[J]. Acta Oncol, 2003, 42(2):123-136.
[6] Girand P, Grahed D, Montravers F, et al. CT and (18)F-deoxyglucose (FDG)image fusion for optimization of conformal radiotherapy of lung cancer[J]. Int J Radiat Oncol Biol Phys, 2001, 49(5):1249-1257.
[7] Bradley JD, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):78-86.
[8] Mah K, Caldwell C, Ung Y, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma:a prospective study[J]. Int J Radiat Oncol Biol Phys, 2002, 52(2):339-350.
[9] Scarfone C, Lavely WC, Cmelak AJ, et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaing[J]. J Nucl Med, 2004, 45(4):543-552.
[10] Ciernik IF, Dizendor E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography(PET-CT):a feasibility study[J]. Int J Radiat Oncol Biol Phys, 2003, 57(3):853-863.
[11] Czernin J, Phelps ME. Positron emission tomography scanning current and future applications[J]. Annual Rev Med, 2002, 53(2):89-112.
[12] Weder W, Schmid RA, Bruchhaus H, et al. Detection of extra thoracic metastases by positron emission tomography in lung cancer[J]. Ann Thorac Surg, 1998, 66(3):886-892.
[13] Dizendort E, Baumert BG, Von Schul-Chess GK, et al. Impact of whole body 18F-FDG PET on staging and managing patients for radiation oncology[J]. J Nucl Med, 2003, 44(1):24-29.
[14] Leviver M, Massager N, Wikler D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors:clinical experience and proposed classification[J]. J Nucl Med, 2004,45(7):1146-1154.
[15] Mutic S, Malyapa RS, Grigsby PW, et al. PET guided IMRT for cervical carcinoma with positive para-aortic lymphnodes:A dose-escalation treatment planning study[J]. Int J Radiat Oncol Biol Phys, 2003,55(1):28-35.
[16] Esthappan J, Mutic S, Malyapa RS, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive para-aortic lymphnodes[J]. Int J Radiat Oncol Biol Phys, 2004, 58(4):1289-1297.
[17] MacManus MP, Hicks RJ, Ball DL, et al. F-18-fluorodexyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma:powerful correlation with survival and high impact on treatment[J]. Cancer, 2001, 92(4):886-895.